164 related articles for article (PubMed ID: 12142389)
1. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
[TBL] [Abstract][Full Text] [Related]
4. Serial serum c-erbB-2 levels in patients with breast carcinoma.
Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
6. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
[TBL] [Abstract][Full Text] [Related]
7. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
8. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
9. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
[TBL] [Abstract][Full Text] [Related]
10. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
11. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
Molina R; Augé JM; Escudero JM; Filella X; Zanon G; Pahisa J; Farrus B; Muñoz M; Velasco M
Tumour Biol; 2010 Jun; 31(3):171-80. PubMed ID: 20361287
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
Yamauchi H; O'Neill A; Gelman R; Carney W; Tenney DY; Hösch S; Hayes DF
J Clin Oncol; 1997 Jul; 15(7):2518-25. PubMed ID: 9215820
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
16. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
17. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
[TBL] [Abstract][Full Text] [Related]
18. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]